ASX Stocks Estimated To Be Trading At A Discount Of Up To 26.3%

Simply Wall St.
18小时前

The Australian market has been experiencing some turbulence, with tariff uncertainties impacting investor sentiment and resulting in a mixed performance across sectors. Amidst this volatility, identifying undervalued stocks can be an attractive strategy for investors looking to capitalize on potential discounts, particularly when the broader market faces headwinds.

Top 10 Undervalued Stocks Based On Cash Flows In Australia

Name Current Price Fair Value (Est) Discount (Est)
Regal Partners (ASX:RPL) A$3.10 A$5.88 47.3%
Acrow (ASX:ACF) A$1.045 A$2.00 47.8%
Domino's Pizza Enterprises (ASX:DMP) A$26.86 A$51.38 47.7%
PointsBet Holdings (ASX:PBH) A$1.085 A$2.14 49.4%
Charter Hall Group (ASX:CHC) A$16.94 A$31.75 46.6%
SciDev (ASX:SDV) A$0.44 A$0.81 45.8%
South32 (ASX:S32) A$3.51 A$6.44 45.5%
Pantoro (ASX:PNR) A$0.135 A$0.26 48.1%
ReadyTech Holdings (ASX:RDY) A$2.79 A$5.14 45.8%
Adriatic Metals (ASX:ADT) A$4.45 A$8.25 46.1%

Click here to see the full list of 43 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Data#3

Overview: Data#3 Limited provides information technology solutions and services across Australia, Fiji, and the Pacific Islands, with a market capitalization of A$1.21 billion.

Operations: The company's revenue is generated from its role as a value-added IT reseller and IT solutions provider, amounting to A$798.05 million.

Estimated Discount To Fair Value: 24.6%

Data#3's current trading price of A$7.80 is 24.6% below its estimated fair value of A$10.34, highlighting potential undervaluation based on cash flows. Despite a recent decline in net income to A$22.35 million, the company anticipates revenue growth of 25% annually, outpacing the Australian market average of 5.8%. However, earnings growth at 10.79% per year lags behind market expectations, and its dividend yield is not fully covered by earnings, which could pose risks for investors seeking sustainable returns.

  • The analysis detailed in our Data#3 growth report hints at robust future financial performance.
  • Unlock comprehensive insights into our analysis of Data#3 stock in this financial health report.
ASX:DTL Discounted Cash Flow as at Mar 2025

Genesis Minerals

Overview: Genesis Minerals Limited focuses on the exploration, production, and development of gold deposits in Western Australia, with a market cap of A$3.58 billion.

Operations: The company generates revenue of A$561.40 million from its activities in mineral production, exploration, and development.

Estimated Discount To Fair Value: 26.3%

Genesis Minerals is trading at A$3.17, significantly below its fair value estimate of A$4.3, suggesting potential undervaluation based on cash flows. The company recently reported strong half-year earnings with net income rising to A$59.8 million from A$24.05 million the previous year, and increased gold production guidance for 2025 to 190,000-210,000 oz. Despite a modest return on equity forecast of 15.8%, Genesis's earnings are expected to grow significantly at 23% annually over the next three years, outpacing the Australian market average growth rate of 11.9%.

  • Our growth report here indicates Genesis Minerals may be poised for an improving outlook.
  • Navigate through the intricacies of Genesis Minerals with our comprehensive financial health report here.
ASX:GMD Discounted Cash Flow as at Mar 2025

Sigma Healthcare

Overview: Sigma Healthcare Limited operates as a pharmaceutical wholesaler, distributor, and pharmacy franchisor in Australia and internationally, with a market cap of A$33.36 billion.

Operations: The company's revenue primarily comes from its Wholesale and Retail Services Segment, generating A$3.29 billion.

Estimated Discount To Fair Value: 26.1%

Sigma Healthcare is trading at A$2.89, below its fair value estimate of A$3.91, indicating potential undervaluation based on cash flows. Despite recent executive changes, the company is poised for robust growth with earnings expected to rise by 30% annually and revenue by 41.2%, both outpacing the Australian market averages. However, significant insider selling and a high level of non-cash earnings could be concerns for investors considering Sigma's long-term stability and liquidity challenges.

  • According our earnings growth report, there's an indication that Sigma Healthcare might be ready to expand.
  • Take a closer look at Sigma Healthcare's balance sheet health here in our report.
ASX:SIG Discounted Cash Flow as at Mar 2025

Make It Happen

  • Delve into our full catalog of 43 Undervalued ASX Stocks Based On Cash Flows here.
  • Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
  • Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Looking For Alternative Opportunities?

  • Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
  • Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
  • Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:DTL ASX:GMD and ASX:SIG.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10